This is the first study to prospectively evaluate the clinical value of novel biomarkers (IL-6, MPO, TNF-alpha) in cancer patients as potential biomarkers of cancer therapy-related cardiac dysfunction, defined according to current ESC cardio-oncology guidelines. Here, IL6 is linked to cancer.